Corporate GovernanceApr 29, 2026, 02:11 PM
ABCL 2026 Annual Meeting: Elect Directors, Ratify E&Y Auditor
AI Summary
AbCellera Biologics Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 11, 2026. Shareholders will vote on the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and a non-binding advisory vote on named executive officer compensation. The company previously dismissed KPMG LLP and engaged Ernst & Young LLP on November 28, 2025. Additionally, Stephen R. Quake was appointed to the Board in November 2025 following Andrew Lo's retirement.
Key Highlights
- 2026 Annual Meeting of Shareholders scheduled virtually for June 11, 2026.
- Shareholders to vote on election of two Class III directors.
- Ratification of Ernst & Young LLP as independent auditor for FY2026.
- KPMG LLP dismissed as auditor on November 28, 2025; Ernst & Young LLP engaged.
- Andrew Lo retired from Board on November 6, 2025; Stephen R. Quake appointed.
- Non-binding advisory vote on named executive officer compensation (Say-on-Pay).
- KPMG LLP audit fees: $775,200 (2024), $997,660 (2025).
- KPMG LLP total fees: $956,974 (2024), $1,004,284 (2025).
Price Impact
More from ABCL